🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

RecruitingNAAges 13 Years - anyAllOman Ministry of Health
NCT07491042 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation. The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * o age equal to or more than13 years. * All genders. * All patients undergoing chronic Peritoneal Dialysis. * Urine output equal or more than 150 ml/24 hours. Exclusion Criteria: * o Age less than 13 years * Patients with type I diabetes mellitus. * Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D). * Patients with urine output less than 150 ml/24hours. * Patients with recurrent hypoglycemic episodes * Patients with acute or chronic liver disease, * Patients who refuse to participate in the study. * peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months
💊

What it tests

  • Dapagliflozin
📍

Where

1 site
Jehad Badawi AL LAHAM
Nizwa, Oman
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy